10 research outputs found
Morphological and functional manifestations of rat adrenal-cortex response to sodium bromide administration under hypodynamic stress
Functional and morphological manifestations of adrenal cortex response to hypodynamia (2-hr immobilization on an operating table) under the influence of bromine preparations were studied. The sodium bromide was administered intraperitoneally in 100, 250, and 500 mg/kg doses once and repeatedly during ten days. The adrenal gland was evaluated functionally by ascorbic acid and cholesterol content and morphologically by coloring it with hematoxylin-eosin and Sudans for lipid revealing at freezing. Results are displayed in two tables and microphotographs. They are summarized as follows: the bromine weakens the functional state of the adrenal cortex in intact rats, causing changes similar to those under stress. During immobilization combined with preliminary bromine administration, a less pronounced stress reaction is noticeable
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
Background: Targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Combining immunotherapies targeting PD-L1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has shown evidence of additive activity in several tumor types. This phase III study evaluated the efficacy of durvalumab (an anti-PD-L1 monoclonal antibody) or durvalumab plus tremelimumab (an anti-CTLA-4 monoclonal antibody) versus standard of care (SoC) in R/M HNSCC patients.
Patients and methods: Patients were randomly assigned to receive 1 : 1 : 1 durvalumab (10 mg/kg every 2 weeks [q2w]), durvalumab plus tremelimumab (durvalumab 20 mg/kg q4w plus tremelimumab 1 mg/kg q4w 4, then durvalumab 10 mg/kg q2w), or SoC (cetuximab, a taxane, methotrexate, or a fluoropyrimidine). The primary end points were overall survival (OS) for durvalumab versus SoC, and OS for durvalumab plus tremelimumab versus SoC. Secondary end points included progression-free survival (PFS), objective response rate, and duration of response. Results: Patients were randomly assigned to receive durvalumab (n 1⁄4 240), durvalumab plus tremelimumab (n 1⁄4 247), or SoC (n 1⁄4 249). No statistically significant improvements in OS were observed for durvalumab versus SoC [hazard ratio (HR): 0.88; 95% confidence interval (CI): 0.72e1.08; P 1⁄4 0.20] or durvalumab plus tremelimumab versus SoC (HR: 1.04; 95% CI: 0.85e1.26; P 1⁄4 0.76). The 12-month survival rates (95% CI) were 37.0% (30.9e43.1), 30.4% (24.7e36.3), and 30.5% (24.7 e36.4) for durvalumab, durvalumab plus tremelimumab, and SoC, respectively. Treatment-related adverse events (trAEs) were consistent with previous reports. The most common trAEs (any grade) were hypothyroidism for durvalumab and durvalumab plus tremelimumab (11.4% and 12.2%, respectively), and anemia (17.5%) for SoC. Grade !3 trAE rates were 10.1%, 16.3%, and 24.2% for durvalumab, durvalumab plus tremelimumab, and SoC, respectively.
Conclusion: There were no statistically significant differences in OS for durvalumab or durvalumab plus tremelimumab versus SoC. However, higher survival rates at 12 to 24 months and response rates demonstrate clinical activity for durvalumab
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
Head and neck squamous cell carcinoma (HNSCC) is
among the 10 most common cancers worldwide, with
increasing incidence.1 Approximately 10% of patients with
HNSCC will be diagnosed with metastatic disease, and
even when treated early, around half will have disease
recurrence.2,3 The platinum-based doublet chemotherapy
with cetuximab regimen has been the most widely-used
therapy and considered standard of care (SoC) since it
was proven effective in 2007 for recurrent/metastatic
(R/M) HNSCC in the first-line setting.3,4 However, patients
typically progress even after aggressive first-line therapy,
and, until recently, the available options (e.g. cetuximab,
methotrexate, and taxanes) have delivered limited survival
benefits.3
Durvalumab is an immunotherapeutic agent that blocks
the interaction between programmed cell death ligand 1
(PD-L1) and its receptors.5 Durvalumab demonstrated
encouraging response rates and duration of response (DoR)
with a manageable safety profile in patients with HNSCC.6
Although monotherapy agents that block the programmed
cell death protein 1 (PD-1)/PD-L1 axis have shown clinical
activity, immunotherapy combinations have the potential
to improve upon monotherapy activity.7e9 Cytotoxic
T-lymphocyte-associated antigen 4 (CTLA-4) and PD-L1/PD-1
pathways have largely non-redundant roles, suggesting
that blockade of both could have additive or synergistic
effects.10 Indeed, the combination of durvalumab and
tremelimumab, an anti-CTLA-4 monoclonal antibody, was
explored based on improved efficacy over monotherapy in
other solid tumor types.7 This observation, in addition to
the activity demonstrated by durvalumab in earlier R/M
HNSCC studies, served as the rationale to evaluate durvalumab
and tremelimumab in patients with R/M HNSCC.
Several studies, including the EAGLE study, were initiated to
evaluate combination immunotherapy regimens in various
patient groups.11,12 The EAGLE study was the first phase III
study to investigate durvalumab and tremelimumab in patients
with R/M HNSCC who had progressed after platinumbased
therapy.
During the conduct of the EAGLE study, anti-PD-1
monoclonal antibodies were approved for use for R/M
HNSCC progression following a platinum-based regimen.
Treatment with these immunotherapies resulted in a median
overall survival (OS) of 7.5e8.4 months.13,14 These
immunotherapies are now recommended for second-line
treatment as monotherapies for patients with R/M
HNSCC.3,13,14 More recently, immunotherapy alone or in
combination with platinum-based chemotherapy has
shown improvements in OS in the first-line setting,
underscoring the clinical utility of immunotherapy in
HNSCC.15
Here, we report the results of the randomized phase III
EAGLE trial evaluating durvalumab and durvalumab plus
tremelimumab versus SoC therapies in patients with R/M
HNSCC who have progressed following a platinumcontaining
regimen
Speech Characteristics of Servants in Italian Comedies of 16<sup>th</sup> Century: on Parameters of Language Variability
The linguistic tools used for the speech characteristics of the servants in Italian comedies of the 16th century are examined. The question is raised about the nature of stylistic marking of speech of the representatives of the lower class, in particular, about which of the parameters of language variability - diaphasia or diastratia - are more often involved by comedians when creating their speech portrait. The novelty of the study is primarily due to the fact that the stylistic features of the speech of the characters of Italian comedies have not previously been considered from the standpoint of the theory of linguistic variability, linguistic pragmatics and historical sociolinguistics. The article proposes a classification of regionally and functionally-stylistically marked linguistic phenomena typical to the servants’ speech in comedies. It is concluded that the main contribution to the creation of the speech portrait of servants is made by the phenomena marked in the diaphasia - linguistic means, the pragmatic function of which prevails over denotative and / or structural. The research continues the cycle of the author’s works devoted to the Italian language of the 16th century and the role of various parameters of language variability in the historical evolution of the Italian language norm
Recommended from our members
Allele-Specific Gene Editing Rescues Pathology in a Human Model of Charcot-Marie-Tooth Disease Type 2E
Many neuromuscular disorders are caused by dominant missense mutations that lead to dominant-negative or gain-of-function pathology. This category of disease is challenging to address via drug treatment or gene augmentation therapy because these strategies may not eliminate the effects of the mutant protein or RNA. Thus, effective treatments are severely lacking for these dominant diseases, which often cause severe disability or death. The targeted inactivation of dominant disease alleles by gene editing is a promising approach with the potential to completely remove the cause of pathology with a single treatment. Here, we demonstrate that allele-specific CRISPR gene editing in a human model of axonal Charcot-Marie-Tooth (CMT) disease rescues pathology caused by a dominant missense mutation in the neurofilament light chain gene (NEFL, CMT type 2E). We utilized a rapid and efficient method for generating spinal motor neurons from human induced pluripotent stem cells (iPSCs) derived from a patient with CMT2E. Diseased motor neurons recapitulated known pathologic phenotypes at early time points of differentiation, including aberrant accumulation of neurofilament light chain protein in neuronal cell bodies. We selectively inactivated the disease NEFL allele in patient iPSCs using Cas9 enzymes to introduce a frameshift at the pathogenic N98S mutation. Motor neurons carrying this allele-specific frameshift demonstrated an amelioration of the disease phenotype comparable to that seen in an isogenic control with precise correction of the mutation. Our results validate allele-specific gene editing as a therapeutic approach for CMT2E and as a promising strategy to silence dominant mutations in any gene for which heterozygous loss-of-function is well tolerated. This highlights the potential for gene editing as a therapy for currently untreatable dominant neurologic diseases